Irritable bowel syndrome: Focus on otilonium bromide

Guy Boeckxstaens, Pere Clavé, Enrico S. Corazziari, Jan Tack

Research output: Contribution to journalReview articleResearchpeer-review

6 Citations (Scopus)


Irritable bowel syndrome is a prevalent and chronic disorder, characterized by recurrent abdominal pain/discomfort, bloating and altered bowel habits. This condition affects an estimated 10-15% of the population worldwide and impacts heavily on a patient's daily life and ability to work, as well as healthcare resource utilization. Drug therapy aimed at correcting the primary symptoms of diarrhea/constipation/bloating may have little effect on abdominal pain, which results from visceral hypersensitivity. Smooth muscle relaxants or antispasmodics decrease the tone and contractility of intestinal smooth muscle, effectively managing abdominal pain. Otilonium bromide has been widely used worldwide and has been found to be safe and well tolerated, and superior to placebo for the reduction of symptoms and the prevention of symptom relapse in patients with irritable bowel syndrome. © 2014 Informa Healthcare.
Original languageEnglish
Pages (from-to)131-137
JournalExpert Review of Gastroenterology and Hepatology
Issue number2
Publication statusPublished - 1 Feb 2014


  • Bromide
  • Impact On Daily Life
  • Irritable Bowel Syndrome
  • Otilonium
  • Spasmolytics
  • Treatment


Dive into the research topics of 'Irritable bowel syndrome: Focus on otilonium bromide'. Together they form a unique fingerprint.

Cite this